Suppr超能文献

系统性红斑狼疮患者外周血淋巴细胞 Toll 样受体的激活谱。

Activation profile of Toll-like receptors of peripheral blood lymphocytes in patients with systemic lupus erythematosus.

机构信息

Department of Chemical Pathology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong.

出版信息

Clin Exp Immunol. 2010 Jan;159(1):11-22. doi: 10.1111/j.1365-2249.2009.04036.x. Epub 2009 Oct 16.

Abstract

Systemic lupus erythematosus (SLE) is a systemic autoimmune disease associated with aberrant activation of T and B lymphocytes for the production of inflammatory cytokines and autoreactive antibodies. Animal studies of SLE have indicated that Toll-like receptors (TLR) are important in the pathogenesis of murine lupus. In the present clinical study, differential protein expressions of TLR-1-9 of monocytes and different lymphocyte subsets from patients with SLE and normal control subjects were determined by flow cytometry. Results showed that the expression of intracellular TLRs (TLR-3, -8, -9) and extracellular TLRs (TLR-1, -2, -4, -5, -6) were elevated in monocytes, CD4(+) T lymphocytes, CD8(+) T lymphocytes and B lymphocytes of SLE patients compared to control subjects (all P < 0.001). Moreover, cell surface expression of TLR-4 on CD4(+) T lymphocytes and CD8(+) T lymphocytes, and TLR-6 on B lymphocytes, were correlated positively with SLE disease activity index (SLEDAI) (TLR-4 on CD4(+) T lymphocytes and CD8(+) T lymphocytes: r = 0.536, P = 0.04; r = 0.713, P = 0.003; TLR-6 in B lymphocytes: r = 0.572, P = 0.026). In concordance with the above results, there is an observable increased relative induction (%) of inflammatory cytokine interleukin (IL)-1beta, IL-6, IL-10 and IL-12, chemokines CCL2, CXCL8, CCL5 and CXCL10 from peripheral blood mononuclear cells (PBMC) upon differential stimulation by PolyIC (TLR-3 ligand), lipopolysaccharide (TLR-4 ligand), peptidoglycan (TLR-2 ligand), flagellin (TLR-5 ligand), R837 (TLR-7 ligand) and CpG DNA (TLR-9 ligand) in SLE patients compared to controls. These results suggest that the innate immune response for extracellular pathogens and self-originated DNA plays immunopathological roles via TLR activation in SLE.

摘要

系统性红斑狼疮(SLE)是一种与 T 和 B 淋巴细胞异常激活有关的自身免疫性疾病,导致炎症细胞因子和自身反应性抗体的产生。SLE 的动物研究表明,Toll 样受体(TLR)在鼠狼疮的发病机制中起重要作用。在本临床研究中,通过流式细胞术测定了 SLE 患者和正常对照者单核细胞和不同淋巴细胞亚群中 TLR-1-9 的差异蛋白表达。结果表明,与对照组相比,SLE 患者的单核细胞、CD4+T 淋巴细胞、CD8+T 淋巴细胞和 B 淋巴细胞中细胞内 TLR(TLR-3、-8、-9)和细胞外 TLR(TLR-1、-2、-4、-5、-6)的表达均升高(均 P<0.001)。此外,CD4+T 淋巴细胞和 CD8+T 淋巴细胞表面 TLR-4 和 B 淋巴细胞表面 TLR-6 的表达与 SLE 疾病活动指数(SLEDAI)呈正相关(CD4+T 淋巴细胞和 CD8+T 淋巴细胞中的 TLR-4:r=0.536,P=0.04;r=0.713,P=0.003;B 淋巴细胞中的 TLR-6:r=0.572,P=0.026)。与上述结果一致,外周血单个核细胞(PBMC)经 PolyIC(TLR-3 配体)、脂多糖(TLR-4 配体)、肽聚糖(TLR-2 配体)、鞭毛蛋白(TLR-5 配体)、R837(TLR-7 配体)和 CpG DNA(TLR-9 配体)差异刺激后,SLE 患者诱导产生的炎症细胞因子白细胞介素(IL)-1β、IL-6、IL-10 和 IL-12,趋化因子 CCL2、CXCL8、CCL5 和 CXCL10 的相对诱导(%)明显高于对照组。这些结果表明,在外源性病原体和自身源性 DNA 的固有免疫反应中,TLR 激活在 SLE 中发挥免疫病理作用。

相似文献

1
Activation profile of Toll-like receptors of peripheral blood lymphocytes in patients with systemic lupus erythematosus.
Clin Exp Immunol. 2010 Jan;159(1):11-22. doi: 10.1111/j.1365-2249.2009.04036.x. Epub 2009 Oct 16.
2
Targeting of TLRs inhibits CD4+ regulatory T cell function and activates lymphocytes in human peripheral blood mononuclear cells.
J Immunol. 2014 Jul 15;193(2):627-34. doi: 10.4049/jimmunol.1203334. Epub 2014 Jun 13.
3
4
Aberrant expression of regulatory cytokine IL-35 in patients with systemic lupus erythematosus.
Lupus. 2015 Oct;24(12):1257-66. doi: 10.1177/0961203315585815. Epub 2015 May 11.
9
Dysregulated balance of Th17 and Th1 cells in systemic lupus erythematosus.
Arthritis Res Ther. 2010;12(2):R53. doi: 10.1186/ar2964. Epub 2010 Mar 24.

引用本文的文献

2
Investigating the therapeutic mechanism of Jiedu-Quyu-Ziyin Fang on systemic lupus erythematosus through the ERα-miRNA-TLR7 immune axis.
Heliyon. 2024 Jun 8;10(12):e32752. doi: 10.1016/j.heliyon.2024.e32752. eCollection 2024 Jun 30.
3
Telitacicept Treatment Refractory Lupus Nephritis: A Case Report.
Case Rep Nephrol Dial. 2024 Mar 22;14(1):42-47. doi: 10.1159/000538033. eCollection 2024 Jan-Dec.
4
Triptoquinone A and B exercise a therapeutic effect in systemic lupus erythematosus by regulating NLRC3.
PeerJ. 2023 Jun 9;11:e15395. doi: 10.7717/peerj.15395. eCollection 2023.
7
Variety of endosomal TLRs and Interferons (IFN-α, IFN-β, IFN-γ) expression profiles in patients with SLE, SSc and MCTD.
Clin Exp Immunol. 2021 Apr;204(1):49-63. doi: 10.1111/cei.13566. Epub 2021 Jan 17.
8
Requisite Omega-3 HUFA Biomarker Thresholds for Preventing Murine Lupus Flaring.
Front Immunol. 2020 Aug 21;11:1796. doi: 10.3389/fimmu.2020.01796. eCollection 2020.
9
Leukocyte toll-like receptor expression in pathergy positive and negative Behçet's disease patients.
Rheumatology (Oxford). 2020 Dec 1;59(12):3971-3979. doi: 10.1093/rheumatology/keaa251.
10
Limited expression of TLR9 on T cells and its functional consequences in patients with nonalcoholic fatty liver disease.
Clin Mol Hepatol. 2020 Apr;26(2):216-226. doi: 10.3350/cmh.2019.0074. Epub 2019 Dec 5.

本文引用的文献

2
Th17 and natural Treg cell population dynamics in systemic lupus erythematosus.
Arthritis Rheum. 2009 May;60(5):1472-83. doi: 10.1002/art.24499.
3
Cytokines in systemic lupus erythematosus.
Curr Mol Med. 2009 Apr;9(3):242-54. doi: 10.2174/156652409787847263.
4
The interleukin-1 receptor/Toll-like receptor superfamily: 10 years of progress.
Immunol Rev. 2008 Dec;226:10-8. doi: 10.1111/j.1600-065X.2008.00701.x.
5
Toll-like receptors in autoimmunity.
Ann N Y Acad Sci. 2008 Nov;1143:21-34. doi: 10.1196/annals.1443.012.
7
Toll-like receptors in systemic lupus erythematosus; prospects for therapeutic intervention.
Autoimmun Rev. 2009 Jan;8(3):204-8. doi: 10.1016/j.autrev.2008.07.046. Epub 2008 Aug 21.
8
Development of TLR inhibitors for the treatment of autoimmune diseases.
Immunol Rev. 2008 Jun;223:271-83. doi: 10.1111/j.1600-065X.2008.00630.x.
10
Chemokines in lupus nephritis.
Front Biosci. 2008 May 1;13:3312-20. doi: 10.2741/2927.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验